alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
| (1)   | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|

| (2)   | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

|        |   |                                  |
|-------------|--------|---------------------------------------|
|        |   |                                  |   |
| May 6, 2010 | By:    | /s/ Michael H. Magusiak          |   |
|        |   | Michael H. Magusiak                   |   |
|        |   | President and Chief Executive Officer |   |
|        |   |                                  |   |
N O T FO R PUB L ICAT IO N UNITED STATES C OUR T OF APPEALS FOR THE NINTH C IR C UIT DONGXING LIN, Pe titione r, v. ER IC H. HOLDER , Jr., Attorne y Ge ne ra l, R

e sponde nt . No. 10-71448 Age n c y No. A099-048-457 M EM O R ANDUM *

On Pe tition for Re vie w of a n Orde r of the B oa rd of Im m igration Appe a ls Subm itte d Oc tobe r 14, 2014 * * B e fore : LEAVY, GOULD, a n d B ER Z ON, C irc uit Judge s . Dongxing Lin, a

nat ive and c itiz e n of C hina , pe t itions pro se for re vie w of the B oa rd of Im m igration Appe a ls’ (“ B IA” ) orde r dism i ssing his a p p e a l from

the im m igration judge ’ s de c i sion de ny i ng his a pplic at ion for a s y lum , withholding of re m ova l, a

nd prote c tion unde r the C onve ntion Agai nst Torture(“ C AT” ). W e have 

# FIL ED NOV 10 2014 M OLLY C. DW Y ER, CLERK U . S . CO URT O F APPEALS

* This disposition is not a ppropria te for public at ion a

nd is not pre c e de nt e xc e pt a s provide d

by 9th C ir. R . 36-3. ** The pa

ne l una nim ously c onc lude s this c a se is suita ble for de c ision without oral a

rgum e nt. Se e Fe d. R . App. P. 34(a)(2).jurisdic tion unde r 8 U.S.C . § 1252. W e re vie w for substa ntia l e vide n c e the a ge nc y ’ s fa c tua l findings. Ze haty ev . Gonzale s , 453 F.3d 1182, 1184-85 (9th C ir. 2006). W e de ny

in pa rt a nd gra nt in pa rt the pe tition for re vie w, a nd we re m and. Substa ntia l e v i de nc e supports the B IA’ s de nia l of Lin’ s C AT c la im be c a use Lin fa ile d to e s ta blish it is m

ore like ly tha n not hewould betorture d. Se e Go v . Holde r , 640 F.3d 1047, 1053-54 (9th C ir. 2011) (pe titione r fa ile d to show suffic i e nt proba

bility of torture to sa

t isfy high C AT sta

nda rd). Thus, Lin’ s C AT c la im fa ils. Substa ntia l e v i de nc e doe s not, howe v e r, support theB IA’ s finding tha t Lin fa ile d to e sta

blish his ac tua l a

nd/or im pute d politic a l opinion wa s or would bea c e ntra l re a s on for a

rre st a nd m istre atm e nt by

the polic e , whe re Lin te stifie d the polic e que stione d him

a bout his a c tions “ t o opposethe gove rnm e nt” and be at him whe n he a sse rte d t

he prote st he le d wa s a

n atte m pt to m a inta in his le ga l rights. Se e Hu v . Holde r , 352 F.3d 1011, 1019 (9th C i r. 2011) (“ Eve n though there m ight ha ve be e n m ultiplem otiva

tions for thegove rnm e nt’ s m istre atm e nt of [the pe titione r] , his c re dible te stim ony

c om pe ls a finding tha

t one of the c e ntra l re a sons for his a lle ge d pe rse c ut ion wa s be c a u s e of a prote c te d ground – his e xpre ssion of a politic a l opinion, ac tua l or im pute d.” ).

1 0 - 7 1 4 4 8

2Thus, we grant Lin’ s pe tition for re vie w with re spe c t to his a sy lum and

withholding of rem o v a l c la im s a nd re m an d for furthe r proc e e dings c onsiste nt with this disposition. Se e IN

S v . Ve n tura , 537 U.S. 12, 16-18 (2002) (pe r c uriam ). Ea c h pa rty sha ll be a r its own c osts for this petition for re vie w . PE T IT IO N FO R RE V IE WDE NIE D in par t; G RANT E D in par t; RE M A NDE D.

1 0 - 7 1 4 4 8 3
Exhibit 32.2 Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.





In
connection with the Quarterly Report of Calgon Carbon Corporation (the
“Company”) on Form 10-Q for the period ended June 30, 2009 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Leroy
M. Ball, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
§ 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
thatto the best of
my knowledge:





(1)  The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2)  The
information contained in the Report fairly presents, in all material respects,
the financial condition and result of operations of the Company for the periods
presented therein.





/s/ Leroy M. BallChief
      Financial OfficerAugust
      7, 2009





This
certification accompanies this Report pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the
Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.
§ 522.1484 Neomycin. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) of neomycin sulfate (equivalent to 35 mg of neomycin base).
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer 5 mg per pound of body weight daily by intramuscular or intravenous injection, divided into portions administered every 6 to 8 hours for 3 to 5 days.
( 2 ) *Indications for use.* For the treatment of acute and chronic bacterial infections due to organisms susceptible to neomycin.
( 3 ) *Limitations.* Not for parenteral use in food-producing animals because of prolonged residues in edible tissues. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16192, Mar. 25, 2014]
§ 582.1 Substances that are generally recognized as safe. ( a ) It is impracticable to list all substances that are generally recognized as safe for their intended use. However, by way of illustration, the Commissioner regards such common food ingredients as salt, pepper, sugar, vinegar, baking powder, and monosodium glutamate as safe for their intended use. The lists in subparts B through H of this part include additional substances that, when used for the purposes indicated, in accordance with good manufacturing or feeding practice, are regarded by the Commissioner as generally recognized as safe for such uses.
( b ) For the purposes of this section, good manufacturing or feeding practice shall be defined to include the following restrictions: ( 1 ) The quantity of a substance added to animal food does not exceed the amount reasonably required to accomplish its intended physical, nutritional, or other technical effect in food; and
( 2 ) The quantity of a substance that becomes a component of animal food as a result of its use in the manufacturing, processing, or packaging of food, and which is not intended to accomplish any physical or other technical effect in the food itself, shall be reduced to the extent reasonably possible.
( 3 ) The substance is of appropriate grade and is prepared and handled as a food ingredient. Upon request the Commissioner will offer an opinion, based on specifications and intended use, as to whether or not a particular grade or lot of the substance is of suitable purity for use in food and would generally be regarded as safe for the purpose intended, by experts qualified to evaluate its safety.
( c ) The inclusion of substances in the list of nutrients does not constitute a finding on the part of the Department that the substance is useful as a supplement to the diet for animals.
( d ) Substances that are generally recognized as safe for their intended use within the meaning of section 409 of the Act are listed in subparts B through H of this part. When the status of a substance has been reevaluated and affirmed as GRAS or deleted from subparts B through H of this part, an appropriate explanation will be noted, e.g., “affirmed as GRAS,” “food additive regulation,” “interim food additive regulation,” or “prohibited from use in food,” with a reference to the appropriate new regulation. Such notation will apply only to the specific use covered by the review, e.g., direct animal food use and/or indirect animal food use and/or animal feed use and will not affect its status for other uses not specified in the referenced regulation, pending a specific review of such other uses.
§ 556.224 Efrotomycin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of efrotomycin is 10 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerance for efrotomycin is: ( 1 ) *Swine.* Edible tissues: Not required.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See § 558.235 of this chapter.
§ 520.2471 Tilmicosin. ( a ) *Specifications.* Each milliliter of concentrate solution contains 250 milligrams (mg) tilmicosin as tilmicosin phosphate.
( b ) *Sponsors.* See Nos. 016592 and 058198 in § 510.600(c) of this chapter.
( c ) *Tolerances.* See § 556.735 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amount.* Administer in drinking water at a concentration of 200 mg per liter for 5 consecutive days.
( 2 ) *Indications for use.* ( i ) For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.
( ii ) For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.
( 3 ) *Limitations.* Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 18158, Apr. 1, 2014, as amended at 81 FR 17608, Mar. 30, 2016; 81 FR 48702, July 26, 2016; 87 FR 58962, Sept. 29, 2022]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7445 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7445

 To prohibit the Administrator of the Federal Aviation Administration 
from authorizing airport space to house undocumented migrants, and for 
                            other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 23, 2024

   Mr. Self (for himself, Mr. Babin, Mr. Perry, Ms. Malliotakis, Ms. 
   Hageman, Mr. Feenstra, Ms. Mace, Mrs. Hinson, Mr. Bishop of North 
  Carolina, Mr. Rosendale, Mrs. Miller of Illinois, Mr. Tiffany, Mr. 
Weber of Texas, Ms. Boebert, and Mr. Davidson) introduced the following 
    bill; which was referred to the Committee on Transportation and 
                             Infrastructure

_______________________________________________________________________

                                 A BILL

 
 To prohibit the Administrator of the Federal Aviation Administration 
from authorizing airport space to house undocumented migrants, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Airport Immigration Enforcement 
Act''.

SEC. 2. HOUSING OF UNDOCUMENTED MIGRANTS.

    The Administrator of the Federal Aviation Administration may not 
authorize airport space to house undocumented migrants.

SEC. 3. PROHIBITING FUNDING FOR HOUSING OF UNDOCUMENTED MIGRANTS AT 
              AIRPORTS.

    No Federal funds may be used to house undocumented migrants in any 
airport.
                                 <all>
```
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA, 

DEPARTMENT OF TRANSPORTATION, 

BUREAU OF DRIVER LICENSING,

Petitioner

v.

QUINN TAYLOR,

Respondent

.

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

No. 7 WAL 2019

Petition for Allowance of Appeal 

from the Order of the 

Commonwealth Court

ORDER

PER CURIAM

AND NOW, this 1st day of March, 2021, the Petition for Allowance of Appeal is 

DENIED.
<PAGE>   1

FOR IMMEDIATE RELEASE

FROM:               THE ACKERLEY GROUP, INC. (206) 624-2888

Analyst Contact:    Dan Evans, Jr., Vice President Public Affairs
                    Denis Curley, Co-President and Chief Financial Officer
                    Leon Berman, The MWW Group (800) 724-7602

Media Contact:      Rosanne Marks, MWW/Savitt (206) 689-8505

--------------------------------------------------------------------------------

                 THE ACKERLEY GROUP TO SELL AK MEDIA/FLORIDA TO
                       CLEAR CHANNEL COMMUNICATIONS, INC.

     SEATTLE -- OCTOBER 26, 1999 -- The Ackerley Group (NYSE: AK), announced
today that the company has signed a letter of intent to sell its Miami/Ft.
Lauderdale and West Palm Beach outdoor billboard business to Eller Media, a
subsidiary of Clear Channel Communications, Inc. (NYSE: CCU) for $300 million
in cash.

     The Company will use the funds from the sale to fuel future acquisitions
in the broadcast, outdoor and sports entertainment markets that benefit The
Ackerley Group's existing media properties. The transaction is subject to the
execution of a formal purchase agreement and to government approval.

     "This sale will allow us to unlock significant value for our shareholders
as we continue to grow the company," said Denis Curley, Co-President/Chief
Financial Officer for The Ackerley Group. "We will continue to aggressively
seek media and entertainment investments and acquisitions consistent with our
cluster strategies."

     "The Ackerley Group is comprised of four operating segments, which
contain a total of 24 independent media and entertainment operations. The
Outdoor Media segment includes outdoor advertising in Seattle/Tacoma, Boston,
Miami/Ft. Lauderdale and Portland, Ore. The Television Broadcasting segment
owns, operates under management agreements, or has applications pending with
the FCC for 13 stations in California, New York, Washington, Oregon and Alaska.
The Radio Broadcasting segment owns and operates four radio stations in the
Seattle-Tacoma market. The Sports & Entertainment segment includes Full House
Sports & Entertainment, the NBA's Seattle SuperSonics and a new WNBA team. For
more information, visit The Ackerley Group web site at www.ackerley.com.
§ 522.1204 Kanamycin. ( a ) *Specifications.* Each milliliter of solution contains 50 or 200 milligrams (mg) of kanamycin as kanamycin sulfate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer by subcutaneous or intramuscular injection 5 mg per pound of body weight per day in equally divided doses at 12-hour intervals.
( 2 ) *Indications for use.* For the treatment of bacterial infections due to kanamycin sensitive organisms in dogs and cats.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16190, Mar. 25, 2014]
§ 74.102 FD&C Blue No. 2. ( a ) *Identity.* ( 1 ) The color additive FD&C Blue No. 2 is principally the disodium salt of 2-(1,3-dihydro-3-oxo-5-sulfo-2*H*-indol-2-ylidene)-2,3-dihydro-3-oxo-1*H*-indole-5-sulfonic acid (CAS Reg. No. 860-22-0) with smaller amounts of the disodium salt of 2-(1,3-dihydro-3-oxo-7-sulfo-2*H*-indol-2-ylidene)-2,3-dihydro-3-oxo-1*H*-indole-5-sulfonic acid (CAS Reg. No. 54947-75-0) and the sodium salt of 2-(1,3-dihydro-3-oxo-2*H*-indol-2-ylidene)-2,3-dihydro-3-oxo-1*H*-indole-5-sulfonic acid (CAS Reg. No. 605-18-5). Additionally, FD&C Blue No. 2 is obtained by heating indigo (or indigo paste) in the presence of sulfuric acid. The color additive is isolated and subjected to purification procedures. The indigo (or indigo paste) used above is manufactured by the fusion of *N*-phenylglycine (prepared from aniline and formaldehyde) in a molten mixture of sodamide and sodium and potassium hydroxides under ammonia pressure. The indigo is isolated and subjected to purification procedures prior to sulfonation.
( 2 ) Color additive mixtures for food use (including dietary supplements) made with FD&C Blue No. 2 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring foods.
( b ) *Specifications.* The color additive FD&C Blue No. 2 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such other impurities may be avoided by current good manufacturing practice: Sum of volatile matter at 135 °C (275 °F) and chlorides and sulfates (calculated as sodium salts), not more than 15 percent. Water insoluble matter, not more than 0.4 percent. Isatin-5-sulfonic acid, not more than 0.4 percent. 5-Sulfoanthranilic acid, not more than 0.2 percent. Disodium salt of 2-(1,3-dihydro-3-oxo-7-sulfo-2*H*-indol-2-ylidene)-2,3-dihydro-3-oxo-1*H*-indole-5-sulfonic acid, not more than 18 percent. Sodium salt of 2-(1,3-dihydro-3-oxo-2*H*-indol-2-ylidene)-2,3-dihydro-3-oxo-1*H*-indole-5-sulfonic acid, not more than 2 percent. Lead (as Pb), not more than 10 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 85 percent.
( c ) *Uses and restrictions.* The color additive FD&C Blue No. 2 may be safely used for coloring foods (including dietary supplements) generally in amounts consistent with current good manufacturing practice except that it may not be used to color foods for which standards of identity have been promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act unless added color is authorized by such standards.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of FD&C Blue No. 2 shall be certified in accordance with regulations in part 80 of this chapter.
[48 FR 5260, Feb. 4, 1983]
#### State of Connecticut *v.*One 1966 Black Cadillac

*Dennis F. Gaffney,*assistant chief prosecuting attorney, for the appellant (state).

Argued April 1

decided April 1, 1969

It appearing that the defendant has failed to defend with proper diligence against the appeal of the state from the judgment of the Appellate Division of the Circuit Court setting aside the judgment of the Circuit Court in the second circuit in favor of the state and ordering a new trial, it is, under Practice Book § 696, ordered that the judgment of the Appellate Division is set aside and the judgment of the Circuit Court in the second circuit is affirmed.
<PAGE>
 
                                   Exhibit 23
                        Consent of KPMG Peat Marwick LLP




                        CONSENT OF INDEPENDENT AUDITORS'

The Board of Directors
The Guarantee Life Companies Inc.:

We consent to incorporation by reference in Registration Statement Nos.
333-17863 and 333-22461 on Form S-8 of The Guarantee Life Companies Inc. of our
reports dated February 13, 1998 relating to the consolidated balance sheets of
The Guarantee Life Companies Inc. and subsidiaries (Guarantee Life) as of
December 31, 1997 and 1996, and the related consolidated statements of income,
comprehensive income, shareholders' equity and cash flows and related schedules
for each of the years in the three-year period ended December 31, 1997, which
reports are included or incorporated by reference in the December 31, 1997
Annual Report on Form 10-K of The Guarantee Life Companies Inc.



                                            KPMG Peat Marwick LLP
Omaha, Nebraska
March 16, 1998
§ 801.45 Devices that must be directly marked with a unique device identifier. ( a ) *In general.* A device that must bear a unique device identifier (UDI) on its label must also bear a permanent marking providing the UDI on the device itself if the device is intended to be used more than once and intended to be reprocessed before each use.
( b ) *UDI for direct marking.* The UDI provided through a direct marking on a device may be: ( 1 ) Identical to the UDI that appears on the label of the device, or
( 2 ) A different UDI used to distinguish the unpackaged device from any device package containing the device.
( c ) *Form of a UDI when provided as a direct marking.* When a device must bear a UDI as a direct marking, the UDI may be provided through either or both of the following: ( 1 ) Easily readable plain-text;
( 2 ) Automatic identification and data capture (AIDC) technology, or any alternative technology, that will provide the UDI of the device on demand.
( d ) *Exceptions.* The requirement of paragraph (a) of this section shall not apply to any device that meets any of the following criteria: ( 1 ) Any type of direct marking would interfere with the safety or effectiveness of the device;
( 2 ) The device cannot be directly marked because it is not technologically feasible;
( 3 ) The device is a single-use device and is subjected to additional processing and manufacturing for the purpose of an additional single use.
( 4 ) The device has been previously marked under paragraph (a) of this section.
( e ) *Exception to be noted in design history file.* A labeler that decides to make use of an exception under paragraph (d of this section) must document the basis of that decision in the design history file required by § 820.30(j) of this chapter.
[78 FR 58818, Sept. 24, 2013]